1. Home
  2. LC vs AGIO Comparison

LC vs AGIO Comparison

Compare LC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LC
  • AGIO
  • Stock Information
  • Founded
  • LC 2006
  • AGIO 2007
  • Country
  • LC United States
  • AGIO United States
  • Employees
  • LC N/A
  • AGIO N/A
  • Industry
  • LC Finance: Consumer Services
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • LC Finance
  • AGIO Health Care
  • Exchange
  • LC Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • LC 1.7B
  • AGIO 1.4B
  • IPO Year
  • LC 2014
  • AGIO 2013
  • Fundamental
  • Price
  • LC $16.30
  • AGIO $38.80
  • Analyst Decision
  • LC Buy
  • AGIO Buy
  • Analyst Count
  • LC 6
  • AGIO 6
  • Target Price
  • LC $16.83
  • AGIO $57.40
  • AVG Volume (30 Days)
  • LC 2.5M
  • AGIO 976.6K
  • Earning Date
  • LC 07-29-2025
  • AGIO 07-31-2025
  • Dividend Yield
  • LC N/A
  • AGIO N/A
  • EPS Growth
  • LC 68.10
  • AGIO N/A
  • EPS
  • LC 0.64
  • AGIO 11.13
  • Revenue
  • LC $1,248,526,000.00
  • AGIO $40,875,000.00
  • Revenue This Year
  • LC N/A
  • AGIO $18.94
  • Revenue Next Year
  • LC $19.23
  • AGIO $201.70
  • P/E Ratio
  • LC $25.43
  • AGIO $3.49
  • Revenue Growth
  • LC 15.90
  • AGIO 30.57
  • 52 Week Low
  • LC $7.90
  • AGIO $23.42
  • 52 Week High
  • LC $18.75
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • LC 66.65
  • AGIO 58.69
  • Support Level
  • LC $14.61
  • AGIO $34.71
  • Resistance Level
  • LC $16.16
  • AGIO $37.73
  • Average True Range (ATR)
  • LC 0.63
  • AGIO 1.50
  • MACD
  • LC -0.07
  • AGIO 0.15
  • Stochastic Oscillator
  • LC 84.50
  • AGIO 82.21

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: